Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 8-K | 10-K | 8-K | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues: |
| International | | | | 66.9 | 59.6 | 59.5 | 55.3 | 55.9 |
| Neuro | | | | 84.8 | 81.1 | 90.4 | 84.7 | 83.6 |
| Vascular | | | | 123.5 | 122.8 | 113.6 | 105.5 | 100.7 |
| Total revenues | 241.4 | 221.2 | 213.7 | 208.3 | 203.9 | 204.0 | 190.1 | 184.3 |
| Revenue growth [+] | 18.4% | 8.4% | 12.4% | 13.1% | 20.5% | 22.2% | 25.8% | 75.3% |
| International | | | | 19.8% | 21.3% | 18.8% | 33.5% | |
| Neuro | | | | 1.5% | 1.3% | 13.3% | 11.5% | 42.0% |
| Vascular | | | | 22.7% | 37.7% | 30.4% | 40.3% | 117.6% |
| Cost of goods sold | 90.3 | 82.8 | 78.4 | 74.3 | 76.5 | 78.6 | 70.2 | 65.6 |
| Gross profit | 151.1 | 138.4 | 135.3 | 134.0 | 127.4 | 125.4 | 119.9 | 118.7 |
| Gross margin | 62.6% | 62.6% | 63.3% | 64.3% | 62.5% | 61.5% | 63.1% | 64.4% |
| Selling, general and administrative [+] | 123.1 | 115.6 | 108.6 | 114.6 | 110.9 | 113.5 | 94.4 | 90.6 |
| General and administrative | | 115.6 | | | | 113.5 | | |
| Research and development | 20.0 | 18.0 | 21.3 | 19.6 | 20.6 | 52.0 | 16.7 | 17.7 |
| Equity in earnings | | | | | | | | |
| EBITDA [+] | | 29.2 | | 5.8 | 1.7 | -34.3 | | 13.9 |
| EBITDA growth | 376.7% | -185.0% | -38.1% | -58.2% | -90.1% | -2102.6% | -152.2% | -195.5% |
| EBITDA margin | 3.3% | 13.2% | 2.5% | 2.8% | 0.8% | -16.8% | 4.6% | 7.5% |
| Depreciation | | 24.3 | | 3.9 | 3.7 | 3.7 | -0.3 | 3.3 |
| EBITA | 8.0 | 4.8 | 5.4 | 1.9 | -2.0 | -38.0 | 9.1 | 10.6 |
| EBITA margin | 3.3% | 2.2% | 2.5% | 0.9% | -1.0% | -18.6% | 4.8% | 5.7% |
| Amortization of intangibles | | | | 2.0 | 2.0 | 2.1 | 0.3 | 0.3 |
| EBIT [+] | 8.0 | 4.8 | 5.4 | -0.1 | -4.0 | -40.1 | 8.8 | 10.3 |
| EBIT growth | -297.9% | -112.1% | -38.1% | -101.3% | -130.1% | 2195.5% | -143.6% | -158.4% |
| EBIT margin | 3.3% | 2.2% | 2.5% | -0.1% | -2.0% | -19.6% | 4.6% | 5.6% |
| Interest income, net [+] | 0.6 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | 0.1 | 0.3 |
| Interest expense | | 0.2 | 0.0 | 0.1 | 0.0 | | | |
| Interest income | 0.6 | 0.1 | | | | 0.0 | 0.1 | 0.3 |
| Other income (expense), net | 0.1 | 2.3 | -2.4 | -1.0 | -1.0 | -0.9 | -1.1 | -0.4 |
| Pre-tax income | 8.7 | 7.1 | 3.0 | -1.2 | -5.1 | -41.0 | 7.8 | 10.2 |
| Income taxes | 0.1 | 3.3 | 5.3 | 2.5 | -5.2 | -16.3 | -0.2 | 1.9 |
| Tax rate | 1.0% | 45.6% | 174.8% | | 101.5% | 39.9% | | 18.7% |
| Minority interest | | | | | | | -0.8 | -0.9 |
| Net income | 8.6 | 3.9 | -2.3 | -3.7 | 0.1 | -24.6 | 8.9 | 9.2 |
| Net margin | 3.5% | 1.8% | -1.1% | -1.8% | 0.0% | -12.1% | 4.7% | 5.0% |
| |
| Basic EPS [+] | $0.22 | $0.10 | ($0.06) | ($0.10) | $0.00 | ($0.66) | $0.24 | $0.25 |
| Growth | 10584.7% | -115.5% | -124.8% | -138.6% | -99.4% | -744.9% | -199.3% | -174.8% |
| Diluted EPS [+] | $0.22 | $0.10 | ($0.06) | ($0.10) | $0.00 | ($0.66) | $0.24 | $0.25 |
| Growth | 10636.3% | -115.2% | -125.5% | -139.7% | -99.4% | -744.9% | -196.7% | -172.7% |
| |
| Shares outstanding (basic) [+] | 38.2 | 38.0 | 37.9 | 37.8 | 37.6 | 37.5 | 36.6 | 36.5 |
| Growth | 1.4% | 1.5% | 3.6% | 3.4% | 3.3% | 4.7% | 1.1% | 3.2% |
| Shares outstanding (diluted) [+] | 39.1 | 38.9 | 37.9 | 37.8 | 38.7 | 37.5 | 37.6 | 37.6 |
| Growth | 0.9% | 3.9% | 0.8% | 0.5% | 3.1% | 4.7% | 3.9% | 6.2% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|